Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

BACKGROUND: Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking. PATIENTS AND METHODS: We prospectively collected clinical and laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Diem, Stefan, Fässler, Mirjam, Hasan Ali, Omar, Siano, Marco, Niederer, Rebekka, Berner, Fiamma, Roux, Guillaume-Alexandre, Ackermann, Christoph Jakob, Schmid, Sabine, Güsewell, Sabine, Früh, Martin, Flatz, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234997/
https://www.ncbi.nlm.nih.gov/pubmed/30519101
http://dx.doi.org/10.2147/CMAR.S179767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234997/
https://www.ncbi.nlm.nih.gov/pubmed/30519101
http://dx.doi.org/10.2147/CMAR.S179767

Ejemplares similares